Richard Miles Hopkins

Biography

 Richard Miles Hopkins has been appointed as Chief Executive Officer of the Company, effective 7, March 2017. Dr Hopkins is an experienced pharmaceutical executive with over 10 years in corporate leadership roles. Most recently, Dr Hopkins held the position of CEO of Phylogica Limited (ASX:PYC) from July 2013. He has an established track record in development of novel cancer therapies with a particular focus on corporate strategy, business development and intellectual property. Dr Hopkins was a co-founder of Phylogica, where, in addition to the CEO role, he served in variety of positions, including Chief Scientific Officer and VP Research and Chief Operating Officer. Dr Hopkins was elected to the position of Chair of Ausbiotech (WA Branch) in 2016. He has also held senior research roles at the Telethon Institute for Child Health Research and the Department of Medicine at the University of Western Australia and Murdoch University. Dr Hopkins will be very important in the continued development of PharmAust’s key anti-cancer product, Monepantel (MPL) as well as assisting with increasing the contract sales and income activities of its wholly owned subsidiary, Epichem Pty Ltd. His experience and capabilities will be an asset to PharmAust and provide an additional level of expertise and knowledge to the Company.

Research Interest

 pharmaceutical technolgy oncology